BioNTech Analysis: $22B Raised
What is BioNTech?
mRNA-based immunotherapies for cancer and infectious diseases
Employees
1001-5000
Founded
2008
Valuation
21.85B
HQ Full Address
An der Goldgrube 12, Mainz, Rhineland-Palatinate 55131, Germany
Revenue Growth Rate
-78%
Product Features & Capabilities
- mRNA cancer immunotherapies
- BNT327 bispecific antibody
- COVID-19 vaccine
- Immunomodulators
- Targeted therapies
Investment Focus
BioNTech is primarily focused on the following therapeutic areas: 1. **Oncology** - Developing innovative cancer therapies. 2. **Infectious Diseases** - Including vaccines for COVID-19, malaria, and tuberculosis. 3. **Autoimmune Diseases** - Exploring treatments for various autoimmune conditions. 4. **Regenerative Medicine** - Advancing therapies in this area. 5. **Allergies and Inflammatory Diseases** - Investigating applications of their technology in these fields.
Other Considerations
Raised €2.25 billion for R&D in 2024; Conducting over 20 Phase 2 and Phase 3 oncology studies; Partnerships with major healthcare organizations; Recognized for scientific excellence in peer-reviewed publications
Latest Funding Round
BioNTech has secured up to $145 million in funding from a global coalition against infectious diseases to help build mRNA vaccine plants in Africa. This funding was announced on May 29, 2024.
Partnerships
- Tempus AI - A multi-year partnership focused on oncology data collaboration to enhance precision medicine. - [Source](https://thehealthcaretechnologyreport.com/tempus-and-biontech-partner-on-oncology-data-collaboration/)
- MediLink Therapeutics - BioNTech expanded its global strategic partnership with MediLink, involving a multi-target ADC technology platform license agreement. - [Source](https://www.prnewswire.com/news-releases/medilink-therapeutics-announces-a-multi-target-tmalin-adc-technology-platform-license-agreement-with-biontech-expanding-their-global-strategic-partnership-302155699.html)
- CEPI (Coalition for Epidemic Preparedness Innovations) - BioNTech and CEPI expanded their partnership to strengthen mRNA vaccine capabilities in Africa, with CEPI committing up to $145 million. - [Source](https://investors.biontech.de/news-releases/news-release-details/biontech-and-cepi-expand-partnership-strengthen-africas-mrna)
- Duality Biologics - A global strategic partnership formed in April 2023 to accelerate the development of differentiated antibody-drug conjugate (ADC) therapeutics. - [Source](https://www.globenewswire.com/news-release/2023/04/03/2639380/0/en/BioNTech-and-DualityBio-Form-Global-Strategic-Partnership-to-Accelerate-Development-of-Differentiated-Antibody-Drug-Conjugate-Therapeutics-for-Solid-Tumors.html)
- Biotheus - A strategic partnership to develop and commercialize a bispecific antibody candidate targeting PD-L1 and VEGF in multiple solid tumor indications. - [Source](https://www.prnewswire.com/news-releases/biotheus-enters-into-strategic-partnership-with-biontech-to-develop-and-commercialize-bispecific-antibody-candidate-targeting-pd-l1-and-vegf-in-multiple-solid-tumor-indications-301978246.html)
Awards Recognition
BioNTech has received several awards and recognitions in the biotech field, including:
1. The German Sustainability Award.
2. The Mustafa Prize.
3. The German Cancer Award.
4. In 2024, BioNTech was awarded "Prime" status by ISS ESG, placing it in the top 10% of all rated companies.
5. The Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY, won the 2023 Prix Galien Canada Innovative Product Award.
1. The German Sustainability Award.
2. The Mustafa Prize.
3. The German Cancer Award.
4. In 2024, BioNTech was awarded "Prime" status by ISS ESG, placing it in the top 10% of all rated companies.
5. The Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY, won the 2023 Prix Galien Canada Innovative Product Award.
Key Innovations
BioNTech has developed several key innovations and products in the biotech sector, particularly in immunotherapy and vaccines. Notably, they are recognized for the Pfizer-BioNTech COVID-19 vaccine, known as Comirnaty, which was the first approved mRNA-based vaccine. Additionally, BioNTech is advancing its oncology pipeline, focusing on personalized cancer immunotherapies and combination therapies that integrate mRNA-based vaccines with other treatment modalities, such as CAR-T cell therapies. The company is also exploring mRNA-based vaccines for various infectious diseases, including malaria and tuberculosis.
Regulatory Approvals
- BNT162b2 (Comirnaty)
- Omicron KP.2-adapted COVID-19 Vaccine - In August 2024, BioNTech and Pfizer received U.S. FDA approval for this updated vaccine to address specific variants of the virus.
- Clinical Trials - BioNTech has received approvals from various regulatory bodies, including the Paul-Ehrlich-Institut in Germany, to conduct clinical trials for its COVID-19 vaccine candidates.
- Fast Track Designation - The U.S. FDA granted Fast Track Designation for BNT111, an investigational cancer immunotherapy.
